Evanson Asset Management LLC Has $469,000 Position in Pfizer Inc. (PFE)
Evanson Asset Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.3% during the second quarter, Holdings Channel reports. The firm owned 13,320 shares of the biopharmaceutical company’s stock after selling 315 shares during the period. Evanson Asset Management LLC’s holdings in Pfizer were worth $469,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the stock. Catamount Wealth Management raised its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. raised its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Oakmont Partners LLC bought a new stake in shares of Pfizer during the second quarter valued at about $211,000. Financial Strategy Network LLC bought a new stake in shares of Pfizer during the first quarter valued at about $205,000. Finally, Moon Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at about $237,000. Institutional investors and hedge funds own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.94% during mid-day trading on Thursday, hitting $32.76. 24,181,890 shares of the stock traded hands. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The stock has a 50-day moving average of $34.14 and a 200 day moving average of $34.26. The stock has a market cap of $198.71 billion, a PE ratio of 29.04 and a beta of 0.86.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.56 EPS. Equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.66%. Pfizer’s payout ratio is currently 95.24%.
Several analysts have recently issued reports on the stock. Argus reiterated a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research report on Sunday, August 28th. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a research note on Monday, June 27th. Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Barclays PLC reissued an “equal weight” rating and issued a $34.00 price target on shares of Pfizer in a research note on Tuesday, August 2nd. Finally, Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.66.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.